Alterity Therapeutics Ltd. has announced the publication of a novel MRI endpoint from the bioMUSE Natural History Study in the peer-reviewed journal Annals of Clinical and Translational Neurology. The study introduces the MSA Atrophy Index (MSA-AI), a new neuroimaging measure developed to diagnose and track disease progression in Multiple System Atrophy $(MSA)$. Utilizing advanced MRI technology, the research demonstrated that statistically significant reductions in brain volume over 12 months correlated with clinical worsening of MSA. The study captured a broad spectrum of clinical severity and atrophy patterns, effectively distinguishing MSA from related synucleinopathies. The results of this study have been presented and are available in the publication entitled "The MSA Atrophy Index (MSA-AI): An Imaging Marker for Diagnosis and Clinical Progression in Multiple System Atrophy."
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。